Atlas Trials

Theravance Biopharma

47 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Theravance Biopharma

RecordFirmDate
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy (NCT05696717)Theravance Biopharma2023-06-27
Phase 4 COPD and Suboptimal Inspiratory Flow Rate (NCT05165485)Theravance Biopharma2022-01-07
TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation (NCT05091723)Theravance Biopharma2021-10-13
Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19 (NCT04681079)Theravance Biopharma2021-05-04
Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects (NCT04688632)Theravance Biopharma2021-01-18
Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects (NCT04587713)Theravance Biopharma2020-10-16
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis (NCT04589260)Theravance Biopharma2020-10-15
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study (NCT03920254)Theravance Biopharma2020-07-23
TD-0903 for ALI Associated With COVID-19 (NCT04402866)Theravance Biopharma2020-06-24
First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19 (NCT04350736)Theravance Biopharma2020-04-23
Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response (NCT04150341)Theravance Biopharma2019-11-06
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (NCT04095793)Theravance Biopharma2019-09-19
Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects (NCT04044339)Theravance Biopharma2019-08-08
Efficacy & Safety of TD-1473 in Ulcerative Colitis (NCT03758443)Theravance Biopharma2019-03-11
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (NCT03829657)Theravance Biopharma2019-02-22
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (NCT03750552)Theravance Biopharma2019-01-24
Multiple Dose Ethnobridging PK Study in Healthy Subjects (NCT03750565)Theravance Biopharma2018-11-27
Efficacy and Safety of TD-1473 in Crohn's Disease (NCT03635112)Theravance Biopharma2018-11-19
Single and Multiple Ascending Dose Study of TD-8236 by Inhalation (NCT03652038)Theravance Biopharma2018-11-07
Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study (NCT03555617)Theravance Biopharma2018-06-13
Drug-Drug Interaction (DDI) Study for TD-9855 (NCT03432793)Theravance Biopharma2018-02-28
TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects (NCT03408470)Theravance Biopharma2018-01-31
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) (NCT02705755)Theravance Biopharma2017-09-09

Track Theravance Biopharma automatically

Every clearance here is in the API, with alerts when new ones post.